TY  - GEN
AU  - Conteduca, Vincenza
AU  - Wetterskog, D
AU  - Sharabiani, M. T. A
AU  - Grande, E
AU  - Fernandez-Perez, M. P
AU  - Jayaram, A
AU  - Salvi, S
AU  - Castellano, D
AU  - Romanel, A
AU  - Lolli, C
AU  - Casadio, V
AU  - Gurioli, G
AU  - Amadori, D
AU  - Font, Albert
AU  - Vazquez-Estevez, S
AU  - Gonzalez del Alba, AranzazuAutor/a del sistema sanitario público de las Islas Baleares Orcid
AU  - Mellado, B
AU  - Fernandez-Calvo, O
AU  - Mendez-Vidal, M. J
AU  - Climent, M. A
AU  - Duran, Ignacio
AU  - Gallardo, E
AU  - Rodriguez, A
AU  - Santander, C
AU  - Saez, M. I
AU  - Puente, J
AU  - Tandefelt, D. Gasi
AU  - Wingate, A
AU  - Dearnaley, D
AU  - Demichelis, F
AU  - De Giorgi, Ugo
AU  - Gonzalez-Billalabeitia, E
AU  - Attard, G
AU  - PREMIERE Collaborators
AU  - Spanish Oncology Genitourinary Grp
PY  - 2017
DO  - 10.1093/annonc/mdx155
SN  - 0923-7534
UR  - http://hdl.handle.net/20.500.12105/20435
AB  - Background: There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex...
LA  - eng
PB  - Oxford University Press
KW  - Castration-resistant prostate cancer
KW  - Androgen receptor
KW  - Plasma DNA
KW  - Enzalutamide
KW  - Abiraterone
KW  - Biomarker
KW  - Disease-Free Survival
TI  - Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
TY  - research article
ER  -